ALCAMENA STEM CELL THERAPEUTICS, LLC
Spencerville, MD · Biotech · Private
REST peptidomimetic peptide (RPP) that inhibits CTDSP1 phosphatase to promote neurotrophic factor expression and nerve regeneration
alcamenabio.com →- Grants
- $3.9M
- 5 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 4
- 1 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Optimization And Assessment Of A Biologic To Improve Cognitive Function After Traumatic Brain Injury | $781,304 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization And Assessment Of A Biologic To Improve Cognitive Function After Traumatic Brain Injury | $543,500 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization And Assessment Of A Biologic To Improve Functional Recovery After Peripheral Nerve Injury | $699,541 | |
| Federal grant | Department of Health and Human Services · Phase I · Optimization And Assessment Of A Biologic To Improve Functional Recovery After Peripheral Nerve Injury | $389,350 | |
| Federal grant | Department of Health and Human Services · Phase II · FDA Phase 1 Development of a Novel Nonopioid Cell and Tissue Permeable Peptide Therapeutic for Epigenetic Reprogramming of Neuropathic Pain | $1,500,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3137 | Sixal Inc | — | — |
| 3138 | Nirogyone Therapeutics LLC | — | — |
| 3139 | SEAK Therapeutics, LLC | — | — |
| 3140 | ALCAMENA STEM CELL THERAPEUTICS, LLC | — | — |
| 3141 | FIBROTHERAPEUTICS INC | — | — |
| 3142 | MARWELL BIO INC. | — | — |
| 3143 | Iria Pharma, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Method of Peptide Library Construction and Peptides Thereofapplication
- Compositions And Methods For Derepressing RE1 Silencing Transcription Factor Target Genesapplication
- Compositions And Methods For Derepressing RE1 Silencing Transcription Factor Target Genesgranted
- Compositions And Methods For Derepressing RE1 Silencing Transcription Factor Target Genesapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.